INLINE CONCENTRATION METER AND CONCENTRATION DETECTION METHOD
    62.
    发明申请
    INLINE CONCENTRATION METER AND CONCENTRATION DETECTION METHOD 审中-公开
    在线浓度计和浓度检测方法

    公开(公告)号:US20160169800A1

    公开(公告)日:2016-06-16

    申请号:US14909424

    申请日:2014-07-18

    Abstract: An inline concentration meter includes a light source unit emitting mixed light containing at least two wavelengths with a phase difference, a detecting unit including a light incident part for entering the mixed light emitted from the light source unit into a fluid passage of a detector body and at least two light detection parts receiving the mixed light passed through the fluid passage, a computing processor unit conducting frequency analyses of detection signals of the mixed light output from the respective light detection parts and computing variations of intensities of the detection signals corresponding to absorbances in at least two frequency ranges to compute a concentration of fluid in the fluid passage based on the variations of the intensities of the detection signals, and a recording/displaying unit recording and displaying a value of the fluid concentration computed at the computing processor unit.

    Abstract translation: 在线浓度计包括发射包含至少两个具有相位差的波长的混合光的光源单元,包括用于将从光源单元发射的混合光进入检测器主体的流体通道的光入射部分的检测单元,以及 接收通过流体通道的混合光的至少两个光检测部件,计算处理器单元,对从各个光检测部分输出的混合光的检测信号进行频率分析,并计算与吸光度对应的检测信号的强度变化 至少两个频率范围,用于基于检测信号的强度的变化计算流体通道中的流体浓度;以及记录/显示单元,记录和显示在计算处理器单元处计算的流体浓度的值。

    MANAGEMENT SYSTEM AND MANAGEMENT METHOD FOR EXPERIMENTAL ANIMAL

    公开(公告)号:US20250098642A2

    公开(公告)日:2025-03-27

    申请号:US18291989

    申请日:2021-08-20

    Abstract: A management system for an experimental animal is provided. This management system includes an information identifying unit configured to identify experimental information on the experimental animal to be transported to an experiment site, and a stress value calculating unit configured to calculate a stress value indicating stress to be suffered by the experimental animal during transportation based on the experimental information. The experimental information includes at least a part of a transportation distance for the transportation of the experimental animal, a transportation period for the transportation of the experimental animal, the number of the experimental animals to be transported at a time, an age of the experimental animal, and information on pretreatment given to the experimental animal prior to the transportation.

    Concentration measuring method, and concentration measuring device

    公开(公告)号:US12078590B2

    公开(公告)日:2024-09-03

    申请号:US17905486

    申请日:2021-03-04

    CPC classification number: G01N21/274 G01N21/314 G01N21/3504

    Abstract: A concentration measurement method performed in a concentration measurement device including an electric unit having a light source and a photodetector, a fluid unit having a measurement cell through which a gas flows, and a processing circuit for calculating a concentration of the gas based on an intensity of a light passing through the measurement cell. The concentration measurement method includes a step of determining an absorption coefficient of the measurement gas using a reference absorption coefficient determined in association with the reference gas and a correction factor associated with the measurement gas, and a step of obtaining a concentration of the measurement gas flowing in the measurement cell using the absorption coefficient of the measurement gas. When the absorption peak wavelength of the measurement gas is longer than the peak wavelength of the light source, a reference gas having a longer absorption peak wavelength than the peak wavelength of the light source is used, and when the absorption peak wavelength of the measurement gas is shorter than the peak wavelength of the light source, a reference gas having a shorter absorption peak wavelength than the peak wavelength of the light source is used.

    MODIFIED NEURAMINIDASE
    69.
    发明申请

    公开(公告)号:US20220364101A1

    公开(公告)日:2022-11-17

    申请号:US17623302

    申请日:2020-07-03

    Abstract: Provided are a modified-type neuraminidase, a gene encoding the modified-type neuraminidase, a combination of the modified-type neuraminidase and cathepsin A, a combination of the gene encoding the modified-type neuraminidase and a gene encoding cathepsin A, a vector including said genes, and a pharmaceutical composition containing same. The pharmaceutical composition can be used for the therapy of lysosomal storage disease.

    MEDICAL Au-Pt-Pd ALLOY
    70.
    发明申请

    公开(公告)号:US20220213576A1

    公开(公告)日:2022-07-07

    申请号:US17607397

    申请日:2020-09-24

    Abstract: The present invention relates to a medical Au—Pt—Pd alloy including Au, Pt, Pd, and inevitable impurities. The alloy has an alloy composition inside a polygon (A1-A2-A3-A4-A5-A6) surrounded by straight lines connected at point A1 (Au: 37.9 atom %, Pt: 0.1 atom %, and Pd: 62 atom %), point A2 (Au: 79.9 atom %, Pt: 0.1 atom %, and Pd: 20 atom %), point A3 (Au: 79.9 atom %, Pt: 20 atom %, and Pd: 0.1 atom %), point A4 (Au: 69.9 atom %, Pt: 30 atom %, and Pd: 0.1 atom %), point A5 (Au: 49 atom %, Pt: 30 atom %, and Pd: 21 atom %), and point A6 (Au: 39 atom %, Pt: 40 atom %, and Pd: 21 atom %) in a Au—Pt—Pd ternary state diagram. The metal structure of the alloy is optimized, and the metal structure is close to a single-phase structure, and has little precipitation of a Au-rich phase and a Pt-rich phase different in composition from a mother phase.

Patent Agency Ranking